Sysmex Astrego


Sysmex Astrego is dedicated to advancing rapid, sensitive, and precise Antibiotic Susceptibility Testing (AST) technology. Founded in 2017 as Astrego Diagnostics and acquired by Sysmex Corporation in 2022, the company develops automated AST systems for near-patient and central laboratory settings. Their technology, based on microfluidics and image analysis, enables detection of bacterial infections and susceptibility testing within 30 minutes, supporting personalized treatment for infections such as UTI, respiratory, and bloodstream infections.

Industries

health-diagnostics
manufacturing
medical-device

Nr. of Employees

small (1-50)

Sysmex Astrego


Products

Desktop analyzer for rapid antibiotic susceptibility testing

A compact, fully automated desktop system designed to detect bacterial growth in clinical samples and perform antibiotic susceptibility testing with a total turnaround time of less than 30 minutes.


Services

Development of assay panels preloaded with antibiotics relevant for specific clinical indications and geographic regions (example: UTI panels).

Supply of a compact, fully automated diagnostic analyzer for rapid detection and susceptibility testing in near-patient and central laboratory settings.

Expertise Areas

  • Antibiotic susceptibility testing (AST)
  • Point-of-care diagnostics
  • Microfluidic device development
  • Single-cell imaging and analysis
  • Show More (3)

Key Technologies

  • Microfluidics
  • Single-cell imaging
  • Automated image analysis
  • Rapid phenotypic AST methods
  • Show More (2)

News & Updates

Page not found. The page might be incorrect or no longer available.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.